The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index; 95 of the 246 sources its claims cite were checked for support.
Hypothyroidism
Open accessAbstract
Hypothyroidism, the deficiency of thyroid hormone, is a common condition worldwide. It affects almost all body systems and has a wide variety of clinical presentations from being asymptomatic to, in rare cases, life threatening. The classic symptoms of hypothyroidism include fatigue, lethargy, weight gain, and cold intolerance; however, these symptoms are non-specific and the diagnosis is typically made on biochemical grounds through serum thyroid function tests. The most common cause of hypothyroidism is chronic autoimmune thyroiditis (Hashimoto's thyroiditis), although other causes, including drugs (such as amiodarone, lithium, and immune checkpoint inhibitors), radioactive-iodine treatment, and thyroid surgery, are frequent. Historically, severe iodine deficiency was the most common cause. Reference ranges for thyroid function tests are based on fixed percentiles of the population distribution, but there is increasing awareness of the need for more individualised reference intervals based on key factors such as age, sex, and special circumstances such as pregnancy. Levothyroxine monotherapy is the standard treatment for hypothyroidism; it is safe and inexpensive, restores thyroid function tests to within the reference range, and improves symptoms in the majority of patients. However, 10% of patients have persistent symptoms of ill health despite normalisation of thyroid function tests biochemically and a substantial proportion of patients on levothyroxine have thyroid-stimulating hormone concentrations outside the reference range. Ongoing symptoms despite levothyroxine treatment has led to some patients using liothyronine or desiccated thyroid extract. Taken together, these factors have led to intense debate around the treatment thresholds and treatment strategies for hypothyroidism. In this Seminar, we review the epidemiology, genetic determinants, causes, and presentation of hypothyroidism; highlight key considerations and controversies in its diagnosis and management; and provide future directions for research.
Overview
CoChat Summary
TL;DR
This Lancet Seminar reviews hypothyroidism epidemiology, genetic determinants, causes, presentation, diagnosis, and management, emphasizing that it is largely a biochemical diagnosis and levothyroxine remains standard therapy. It highlights persistent controversies around treatment thresholds, individualized reference ranges, and management of patients with residual symptoms despite biochemical euthyroidism.
Key findings
- In iodine-sufficient countries, overt hypothyroidism prevalence is approximately 1–2%; hypothyroidism (subclinical and overt) is about 10-times more common in women than men, and prevalence reaches as high as 7% in individuals aged 85–89 years when age-related reference ranges are not used.
- Hashimoto’s thyroiditis is the most common cause; TPO-Ab are present in approximately 11% of the general population, twin studies estimate ~65% of variance is genetic, and a polygenic risk score in the highest vs lowest quartile was associated with subclinical hypothyroidism (OR 1.80, 95% CI 1.27–2.55) and overt hypothyroidism (OR 1.89, 95% CI 1.24–2.87).
- Levothyroxine monotherapy is standard, but 25–40% of patients on long-term treatment have TSH below or above the reference range; 10–15% express dissatisfaction despite TSH normalization, and systematic reviews/meta-analyses of 18 trials found no clear benefit of combination levothyroxine-liothyronine over monotherapy.
- Iatrogenic hypothyroidism is frequent: after radioactive iodine for Graves’ disease, hypothyroidism occurred in 80.7% within 12 months; lithium causes overt hypothyroidism in 5–15%; tyrosine kinase inhibitors led up to 27% requiring levothyroxine; external-beam radiotherapy for head and neck cancers has incidence around 20–30%.
Methods
- Design: narrative Seminar/review synthesizing epidemiology, genetic determinants, causes, presentation, diagnosis, and management of hypothyroidism; not a systematic review or meta-analysis.
- Data/sample: published literature, guidelines, population studies, genetic studies, RCTs, and meta-analyses; the contribution statement says PNT and MMM performed the literature search and all authors selected studies and drafted sections.
- Analysis: narrative synthesis with selected quantitative estimates and guideline recommendations; no formal pooled analysis reported.
Limitations
- Stated: evidence on subclinical hypothyroidism treatment is uncertain, with no definitive trial in younger individuals; observational studies are susceptible to confounding, reverse causation, and other biases; combination levothyroxine-liothyronine trials had small sample sizes, inadequate liothyronine dosing, often did not enroll patients with persistent symptoms despite biochemical euthyroidism, and did not use latest thyroid-specific outcome measures such as ThyPRO.
- Stated: current polygenic risk scores for thyroid function are too limited by discriminatory power for clinical practice.
- Evident: as a narrative Seminar, it does not report a systematic search strategy, formal study selection, risk-of-bias assessment, or quantitative synthesis, so recommendations rely on narrative interpretation of heterogeneous evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
72 Valid · 7 Not valid · 91 Not checked · 13 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In subclinical hypothyroidism, TPO-Ab positivity is an important risk factor for progression to overt disease.25”
What the sources say
- Partly supportedcites [25] Walsh, 2010, Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Table 5 (Discussion; page unavailable) shows that higher baseline TPOAb concentrations predicted overt hypothyroidism at follow-up, including after adjustment for age, sex, and TSH. But that analysis covers the whole cohort, not specifically people with subclinical hypothyroidism at baseline. Table 7 examines those with elevated baseline TSH, but groups TPOAb and TgAb together as positive thyroid antibodies, so it does not isolate TPOAb positivity in that subgroup. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, 25-40% of patients on long-term levothyroxine treatment have a TSH concentration below or above the reference range.7,9,10”
What the sources say
- Supportedcites [7] Taylor, 2014, Falling threshold for treatment of borderline elevated thyrotropin levels—balancing benefits and risks: evidence from a large community-based study, JAMA Intern Med source
The section “Thyrotropin Levels After Initiation of Levothyroxine Therapy” (page not available) reports that, five years after treatment began, 5.8% had TSH below 0.1 mIU/L, 10.2% had 0.1–0.5, 18.8% had 5.0–10.0, and 2.7% had above 10.0. These total 37.5% below or above the stated range, within the claimed 25–40%. The five-year figures are based on patients with a follow-up TSH measurement, not all treated patients. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [9] Parle, 1993, Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment, Br J Gen Pract
- Not checked — no full text of the sourcecites [10] Canaris, 2000, The Colorado thyroid disease prevalence study, Arch Intern Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In older individuals (>65 years), the reference range for TSH is shifted towards higher values, with the 97•5th percentile of the confidence interval for serum TSH in healthy older people being around 7•5 mIU/L.3”
What the sources say
- Partly supportedcites [3] Taylor, 2018, Global epidemiology of hyperthyroidism and hypothyroidism, Nat Rev Endocrinol sourceExperimental — accuracy not yet measured
The hypothyroidism discussion says that, without age-specific TSH reference ranges, an ageing population is likely to show a higher prevalence of hypothyroidism. This supports the relevance of age to TSH interpretation, but our copy does not give a 97.5th-percentile value of about 7.5 mIU/L for healthy people over 65. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is increasing evidence that variation in thyroid status within the reference range is a risk factor for disease burden.[115][116][117][118]”
What the sources say
- Not checked — no full text of the sourcecites [115] Dayan, 2002, Whose normal thyroid function is better—yours or mine?, Lancet source
- Not checked — no full text of the sourcecites [116] Taylor, 2013, A review of the clinical consequences of variation in thyroid function within the reference range, J Clin Endocrinol Metab source
- Supportedcites [117] Chaker, 2017, Defining optimal health range for thyroid function based on the risk of cardiovascular disease, J Clin Endocrinol Metab source
The Introduction (p. 4) says that differences in thyroid function within the reference range are associated with differing risks of cardiovascular events, including stroke and cardiovascular mortality. This supports the cited statement about disease risk within the reference range. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most common symptoms of hypothyroidism in adults are lethargy, fatigue, cold intolerance, weight gain, hoarse voice, and dry skin.4”
What the sources say
- Partly supportedcites [4] Canaris, 1997, Do traditional symptoms of hypothyroidism correlate with biochemical disease?, J Gen Intern Med sourceExperimental — accuracy not yet measured
In the Results (Table 2; page not specified), dry skin, cold sensitivity, and tiredness were reported by 71%, 51%, and 40% of hypothyroid patients, respectively. Hoarse voice was reported by only 17%, so the table does not establish it as one of the most common symptoms. The paper does not report weight gain or lethargy as distinct symptoms. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
80 more claims · 35 with their cited sources checked
Create a free account to see all 183 claims and to verify the 4 references still open.
- It may state two separate claims as one. 70
- Probably not a substantial claim. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In primary hypothyroidism, the addition of twice-daily 3,5,3′-triiodothyronine (T3) replacement to levothyroxine is considered, especially if T3 levels are low, if individuals have persistent symptoms that could be related to hypothyroidism (22).”
From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ References
“110. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. JAMA 2007; 167: 1533-38.”
§ References
“145. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007; 167: 1533-38.”
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey
Vanderpump, M. P. J., Tunbrldge, W. M. G., French, J. M., Appleton, D., Bates, D., Clark, F., Evans, J. G., Hasan, D. M., Rodgers, H., Tunbridge, F., et al. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01894.x · Cited by 2,432
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Self-citationVaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Zimmermann, M. B. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0011 · Cited by 1,071
Research works printed but not linked: 3
- Hashimoto, 1912, Zur Kenntniss der lymphomatosen Verandererung der Schilddrüse (Struma lymphomatosa), Arch Klin Chirugie, 97, 219
- Meyerovitch, 2007, Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians, JAMA, 167, 1533
- Garber, 2012, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association, Endocr Pract, 18, 988, 10.4158/EP12280.GL · DOI · Paper page
Cited by
Thyroid Hormones and Metabolism Regulation: Which Role on Brown Adipose Tissue and Browning Process?
Sabatino, L., & Vassalle, C. (2025) · Biomolecules · doi:10.3390/biom15030361 · Cited by 58
A Scoping Review on the Prevalence of Hashimoto’s Thyroiditis and the Possible Associated Factors
Vargas‐Uricoechea, H., Castellanos-Pinedo, A., Urrego-Noguera, K., Fernández, M. V. P., Meza-Cabrera, I. A., & Vargas-Sierra, H. D. (2025) · Medical Sciences · doi:10.3390/medsci13020043 · Cited by 58
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
Mao, X., Mao, C., Liu, J., Wang, X., & Mao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1584675 · Cited by 22
Metabolic and Functional Cross Talk Between the Thyroid and Liver
Chng, C. L., Goh, G. B., & Yen, P. M. (2025) · Thyroid · doi:10.1089/thy.2025.0178 · Cited by 37
Toxicities in long‐term survivors of head and neck cancer—A multi‐national cross‐sectional analysis
Taylor, K., Amdal, C. D., Bjordal, K., Astrup, G. L., Herlofson, B. B., Duprez, F., Gama, R. R., Jacinto, A. A., Hammerlid, E. B., Scricciolo, M., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70033 · Cited by 17
Metadata
- Authors
- Taylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K.
- Affiliations
- Cardiff University (GB)
- Erasmus MC (NL)
- University of Birmingham (GB)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 404
- Issue
- 10460
- Pages
- 1347-1364
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4403094217
- Cited by
- 128
- References
- 203
- Citations by year
- 2026: 59 · 2025: 66 · 2024: 2
- FWCI
- 31.13
- Type
- journal article
- Language
- en
- Open access
- green
- orca.cardiff.ac.uk
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroscience of respiration and sleep
- Keywords
- hypothyroidism, thyroid hormone deficiency, Hashimoto's thyroiditis, autoimmune thyroiditis, drug-induced hypothyroidism, thyroid surgery, iodine deficiency, thyroid function tests
- MeSH terms
- Female, Humans, Hypothyroidism, Pregnancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypothyroidism. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01614-3
- The paper
- Taylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024). Hypothyroidism. The Lancet. https://doi.org/10.1016/s0140-6736(24)01614-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.